{"gene":"CRYL1","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2003,"finding":"Human CRYL1 encodes a protein sharing 83% identity with rabbit lambda-crystallin and contains two HCDH (3-hydroxyacyl-CoA dehydrogenase) domains, including a putative NAD- or FAD-binding domain, suggesting enzymatic activity analogous to 3-hydroxyacyl-CoA dehydrogenase. CRYL1 mRNA is highly expressed in liver and kidney but extremely low in peripheral blood leukocytes and thymus.","method":"cDNA cloning, sequence analysis, domain identification, Northern blot/expression profiling, chromosomal mapping","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2/3 / Weak — domain identification and expression profiling from a single lab; enzymatic activity inferred from domain homology, not directly assayed","pmids":["12527201"],"is_preprint":false},{"year":2003,"finding":"CRYL1 mRNA is downregulated in 58% of 60 hepatocellular carcinoma (HCC) tissue samples compared to normal liver, consistent with a tumor suppressor role.","method":"Differential gene expression analysis between liver cancer and normal tissues","journal":"Gene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, expression-level finding without direct functional mechanism established","pmids":["12527201"],"is_preprint":false},{"year":2005,"finding":"CRYL1, along with TG737 and GJB2, is significantly downregulated within a homozygous deletion region at 13q12.11 in HCC, and LOH at this locus is associated with early-onset HCC, supporting CRYL1 as a candidate tumor suppressor gene.","method":"High-density genetic marker scan, Southern blotting, LOH analysis, quantitative RT-PCR in 48 HCC tissue pairs","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative RT-PCR on patient tissue pairs with LOH analysis; multiple methods but no direct functional assay of CRYL1 protein","pmids":["16075462"],"is_preprint":false},{"year":2017,"finding":"A recurrent CRYL1-IFT88 chimeric fusion transcript was identified in hepatocellular carcinoma (recurrence rate ~9.52%, 6/63 samples). The fusion transcript retains most of the CRYL1 domain structure, while the IFT88 transcript structure is entirely disrupted, potentially suppressing IFT88 tumor suppressor function.","method":"Transcriptome sequencing, RT-PCR validation, 3' and 5' RACE for full-length fusion transcript characterization","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fusion transcript validated by multiple methods (RNA-seq, RT-PCR, RACE) across multiple samples in a single study; functional consequence for IFT88 inferred bioinformatically","pmids":["28489570"],"is_preprint":false},{"year":2017,"finding":"CRYL1 was identified as a cadmium-responsive gene in zebrafish embryos and adult retinae; CRYL1 (described as a lens protein with redox activity) expression was upregulated in retinal cells following cadmium exposure in a dose-dependent manner, and expression returned to baseline upon cadmium removal.","method":"In situ hybridization, dose-response analysis in zebrafish exposed to cadmium","journal":"Comptes rendus biologies","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method (ISH), functional mechanism not directly tested","pmids":["28385620"],"is_preprint":false},{"year":2025,"finding":"A novel 200 kb deletion spanning the entire CRYL1 gene causes DFNB1A nonsyndromic sensorineural hearing loss when in trans with pathogenic GJB2 variants. CRYL1 deletions (overlapping a minimal common 62 kb region within CRYL1) cause loss of cis GJB2 expression, establishing that CRYL1 genomic sequences contain cis-regulatory elements required for GJB2 expression in the cochlea.","method":"Panel NGS, MLPA, whole-genome sequencing breakpoint mapping, PCR + Sanger sequencing, triple-primer PCR screening","journal":"Genes","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (NGS, WGS, MLPA, Sanger) and replicated across multiple independent deletions from different groups demonstrating the same cis-regulatory mechanism","pmids":["40565562","19101659","41367487"],"is_preprint":false},{"year":2026,"finding":"CRYL1 overexpression in clear cell renal cell carcinoma (ccRCC) cell lines (Caki-1, OSRC-2) suppressed proliferation, colony formation, and migration, and induced apoptosis. Transcriptome sequencing identified CASR (calcium-sensing receptor) as a key downstream target upregulated by CRYL1. CASR knockdown partially reversed the anti-migratory effects of CRYL1 overexpression, establishing a CRYL1/CASR signaling axis. In vivo, CRYL1-overexpressing xenografts showed reduced tumor growth, upregulated BAX and TIMP3, and downregulated BCL2 and MMP9.","method":"In vitro proliferation, migration, and apoptosis assays; transcriptome sequencing; bioinformatics; rescue (CASR knockdown) experiments; IHC; subcutaneous xenograft mouse models","journal":"Cancer genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods from a single lab; rescue experiment places CASR downstream of CRYL1 in the pathway","pmids":["42105605"],"is_preprint":false}],"current_model":"CRYL1 encodes a protein with two HCDH (3-hydroxyacyl-CoA dehydrogenase-like) domains and putative NAD/FAD-binding activity; it is highly expressed in liver and kidney, functions as a tumor suppressor in hepatocellular carcinoma and clear cell renal cell carcinoma (suppressing proliferation and migration at least in part by upregulating CASR), and its genomic locus contains cis-regulatory sequences essential for GJB2 cochlear expression such that deletions spanning CRYL1 cause nonsyndromic sensorineural hearing loss."},"narrative":{"mechanistic_narrative":"CRYL1 encodes a metabolic enzyme of the 3-hydroxyacyl-CoA dehydrogenase family, defined by two HCDH domains including a putative NAD/FAD-binding domain and 83% identity to rabbit lambda-crystallin, with mRNA expression concentrated in liver and kidney [PMID:12527201]. It functions as a candidate tumor suppressor: its expression is downregulated in the majority of hepatocellular carcinomas and lost through homozygous deletion and LOH at 13q12.11, where loss correlates with early-onset disease [PMID:12527201, PMID:16075462]. In clear cell renal cell carcinoma, CRYL1 overexpression suppresses proliferation, colony formation, and migration and induces apoptosis, acting at least in part through upregulation of the calcium-sensing receptor CASR, whose knockdown partially reverses the anti-migratory phenotype, and in xenografts shifts the cell toward a pro-apoptotic, anti-invasive program (elevated BAX and TIMP3, reduced BCL2 and MMP9) [PMID:42105605]. Independently of any protein function, the CRYL1 genomic locus harbors cis-regulatory elements required for cochlear GJB2 expression: deletions spanning CRYL1 in trans with pathogenic GJB2 variants cause DFNB1A nonsyndromic sensorineural hearing loss by abolishing cis GJB2 expression [PMID:40565562, PMID:19101659, PMID:41367487]. The enzymatic activity inferred from its HCDH domains has not been directly assayed in the available corpus.","teleology":[{"year":2003,"claim":"Establishing the molecular identity of CRYL1 was the first step: the question was what kind of protein it encodes and where it acts, answered by domain architecture and tissue expression.","evidence":"cDNA cloning, sequence/domain analysis, and Northern blot expression profiling","pmids":["12527201"],"confidence":"Medium","gaps":["Enzymatic activity was inferred from domain homology, not directly assayed","No substrate identified","No structural model of the HCDH domains"]},{"year":2003,"claim":"Whether CRYL1 expression is altered in cancer was addressed by showing downregulation in a majority of hepatocellular carcinomas, raising the tumor suppressor hypothesis.","evidence":"Differential gene expression analysis between HCC and normal liver tissue","pmids":["12527201"],"confidence":"Low","gaps":["Expression-level association only; no functional mechanism tested","Does not establish causality or the basis of downregulation"]},{"year":2005,"claim":"The genetic basis of CRYL1 loss in liver cancer was clarified by mapping homozygous deletion and LOH at 13q12.11, supporting a candidate tumor suppressor at this locus.","evidence":"Genetic marker scan, Southern blotting, LOH analysis, and quantitative RT-PCR in HCC tissue pairs","pmids":["16075462"],"confidence":"Medium","gaps":["No direct functional assay of CRYL1 protein in HCC","Deletion spans multiple genes (TG737, GJB2), confounding gene-specific attribution"]},{"year":2017,"claim":"A recurrent CRYL1-IFT88 fusion transcript in HCC raised the possibility that CRYL1 locus rearrangement contributes to tumorigenesis by disrupting IFT88.","evidence":"Transcriptome sequencing, RT-PCR validation, and 5'/3' RACE characterization","pmids":["28489570"],"confidence":"Medium","gaps":["Functional consequence for IFT88 inferred bioinformatically, not tested experimentally","Role of the retained CRYL1 portion in the fusion unknown"]},{"year":2017,"claim":"Whether CRYL1 responds to environmental stress was probed by showing cadmium-inducible expression in zebrafish retina, hinting at a redox-related stress role.","evidence":"In situ hybridization and dose-response analysis in cadmium-exposed zebrafish","pmids":["28385620"],"confidence":"Low","gaps":["Single method (ISH); functional mechanism not tested","No link to the proposed enzymatic activity established"]},{"year":2025,"claim":"The hearing-loss phenotype of CRYL1 deletions was resolved as a positional/cis-regulatory effect rather than loss of CRYL1 protein, showing the locus carries elements required for cochlear GJB2 expression.","evidence":"Panel NGS, MLPA, whole-genome breakpoint mapping, and Sanger sequencing across multiple independent deletions in trans with GJB2 variants","pmids":["40565562","19101659","41367487"],"confidence":"High","gaps":["Precise regulatory elements and their interaction with GJB2 not mapped at base resolution","Does not implicate CRYL1 protein function in hearing"]},{"year":2026,"claim":"A functional tumor suppressor mechanism was finally provided by showing CRYL1 overexpression suppresses ccRCC growth and migration via upregulation of CASR.","evidence":"In vitro proliferation/migration/apoptosis assays, transcriptome sequencing, CASR-knockdown rescue, IHC, and xenograft models","pmids":["42105605"],"confidence":"Medium","gaps":["Single lab; rescue was only partial, implying additional effectors","Mechanism linking CRYL1 enzymatic activity to CASR transcription unknown","Whether the same axis operates in HCC not tested"]},{"year":null,"claim":"The direct biochemical activity of CRYL1 and how it mechanistically connects to tumor suppression and downstream CASR signaling remain unresolved.","evidence":"No reconstituted enzymatic or substrate assay reported in the corpus","pmids":[],"confidence":"Low","gaps":["No enzymatic substrate or catalytic readout demonstrated","Causal chain from a metabolic/redox activity to CASR upregulation unknown","No structural characterization"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0]}],"localization":[],"pathway":[],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y2S2","full_name":"Lambda-crystallin homolog","aliases":["L-gulonate 3-dehydrogenase","Gul3DH"],"length_aa":319,"mass_kda":35.4,"function":"Catalyzes the conversion of L-gulonate to 3-dehydro-L-gulonate (PubMed:15809331, PubMed:40737316). It also exhibits low dehydrogenase activity toward L-3-hydroxybutyrate (HBA) and L-threonate (PubMed:15809331). Utilizes NAD as the sole cosubstrate and shows no activity with NADP (PubMed:40737316)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y2S2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CRYL1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CRYL1","total_profiled":1310},"omim":[{"mim_id":"609877","title":"CRYSTALLIN, LAMBDA-1; CRYL1","url":"https://www.omim.org/entry/609877"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nucleoli","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"kidney","ntpm":307.7},{"tissue":"liver","ntpm":237.5}],"url":"https://www.proteinatlas.org/search/CRYL1"},"hgnc":{"alias_symbol":["GDH","lambda-CRY","MGC149525","MGC149526"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y2S2","domains":[{"cath_id":"3.40.50.720","chopping":"7-184","consensus_level":"high","plddt":98.1302,"start":7,"end":184},{"cath_id":"1.10.1040.10","chopping":"194-287","consensus_level":"high","plddt":97.2315,"start":194,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2S2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2S2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2S2-F1-predicted_aligned_error_v6.png","plddt_mean":96.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CRYL1","jax_strain_url":"https://www.jax.org/strain/search?query=CRYL1"},"sequence":{"accession":"Q9Y2S2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y2S2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y2S2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2S2"}},"corpus_meta":[{"pmid":"24958192","id":"PMC_24958192","title":"Genome-wide association interaction analysis for Alzheimer's disease.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24958192","citation_count":52,"is_preprint":false},{"pmid":"19101659","id":"PMC_19101659","title":"A new large deletion in the DFNB1 locus causes nonsyndromic hearing loss.","date":"2008","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19101659","citation_count":38,"is_preprint":false},{"pmid":"12527201","id":"PMC_12527201","title":"Human CRYL1, a novel enzyme-crystallin overexpressed in liver and kidney and downregulated in 58% of liver cancer tissues from 60 Chinese patients, and four new homologs from other mammalians.","date":"2003","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/12527201","citation_count":29,"is_preprint":false},{"pmid":"32582192","id":"PMC_32582192","title":"Absence of miRNA-146a Differentially Alters Microglia Function and Proteome.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32582192","citation_count":28,"is_preprint":false},{"pmid":"28206976","id":"PMC_28206976","title":"Lipid and Alzheimer's disease genes associated with healthy aging and longevity in healthy oldest-old.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28206976","citation_count":27,"is_preprint":false},{"pmid":"16075462","id":"PMC_16075462","title":"Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11.","date":"2005","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16075462","citation_count":27,"is_preprint":false},{"pmid":"17321332","id":"PMC_17321332","title":"Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.","date":"2007","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17321332","citation_count":19,"is_preprint":false},{"pmid":"24156272","id":"PMC_24156272","title":"Optimization of simultaneous screening of the main mutations involved in non-syndromic deafness using the TaqMan® OpenArray™ Genotyping platform.","date":"2013","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24156272","citation_count":16,"is_preprint":false},{"pmid":"33921578","id":"PMC_33921578","title":"Multi-Omics Analysis of Key microRNA-mRNA Metabolic Regulatory Networks in Skeletal Muscle of Obese Rabbits.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33921578","citation_count":13,"is_preprint":false},{"pmid":"28489570","id":"PMC_28489570","title":"Transcriptome profiling identifies a recurrent CRYL1-IFT88 chimeric transcript in hepatocellular carcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28489570","citation_count":12,"is_preprint":false},{"pmid":"37630778","id":"PMC_37630778","title":"The Microbiome, Epigenome, and Diet in Adults with Obesity during Behavioral Weight Loss.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/37630778","citation_count":8,"is_preprint":false},{"pmid":"20018183","id":"PMC_20018183","title":"Hematopoietic neoplastic diseases develop in C3H/He and C57BL/6 mice after benzene exposure: strain differences in bone marrow tissue responses observed using microarrays.","date":"2009","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/20018183","citation_count":8,"is_preprint":false},{"pmid":"36607984","id":"PMC_36607984","title":"Genome-wide association study of abdominal MRI-measured visceral fat: The multiethnic cohort adiposity phenotype study.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36607984","citation_count":6,"is_preprint":false},{"pmid":"36399516","id":"PMC_36399516","title":"Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36399516","citation_count":5,"is_preprint":false},{"pmid":"38791464","id":"PMC_38791464","title":"Systematic Review of Genetic Modifiers Associated with the Development and/or Progression of Nephropathy in Patients with Sickle Cell Disease.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38791464","citation_count":5,"is_preprint":false},{"pmid":"40782403","id":"PMC_40782403","title":"Route-specific ecotoxicogenomic responses of the honey bee Apis mellifera to imidacloprid revealed by co-expression analysis.","date":"2025","source":"The Science of the total environment","url":"https://pubmed.ncbi.nlm.nih.gov/40782403","citation_count":4,"is_preprint":false},{"pmid":"40565562","id":"PMC_40565562","title":"A Novel Recurrent 200 kb CRYL1 Deletion Underlies DFNB1A Hearing Loss in Patients from Northwestern Spain.","date":"2025","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/40565562","citation_count":3,"is_preprint":false},{"pmid":"36996265","id":"PMC_36996265","title":"Blood transcriptome of Rasa Aragonesa rams with different sexual behavior phenotype reveals CRYL1 and SORCS2 as genes associated with this trait.","date":"2023","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/36996265","citation_count":3,"is_preprint":false},{"pmid":"28385620","id":"PMC_28385620","title":"Retinoblastoma binding protein 6 and crystallin lambda 1 are cadmium-responsive genes in zebrafish embryos and adults retinae.","date":"2017","source":"Comptes rendus biologies","url":"https://pubmed.ncbi.nlm.nih.gov/28385620","citation_count":3,"is_preprint":false},{"pmid":"37958061","id":"PMC_37958061","title":"Four Markers Useful for the Distinction of Intrauterine Growth Restriction in Sheep.","date":"2023","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/37958061","citation_count":3,"is_preprint":false},{"pmid":"40719369","id":"PMC_40719369","title":"Clinical and Genetic Predictors of Sickle Cell Nephropathy: A Global Systematic Review.","date":"2025","source":"Omics : a journal of integrative biology","url":"https://pubmed.ncbi.nlm.nih.gov/40719369","citation_count":2,"is_preprint":false},{"pmid":"41516362","id":"PMC_41516362","title":"GJB2-Related Hearing Loss: Genotype-Phenotype Correlations, Natural History, and Emerging Therapeutic Strategies.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41516362","citation_count":1,"is_preprint":false},{"pmid":"41472678","id":"PMC_41472678","title":"Multi-cohort genome-wide association analyses reveal loci underlying circulating liver enzyme levels in African-ancestry populations.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/41472678","citation_count":1,"is_preprint":false},{"pmid":"42105605","id":"PMC_42105605","title":"CRYL1 inhibits tumorigenesis and metastasis in clear cell renal cell carcinoma through upregulation of CASR.","date":"2026","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/42105605","citation_count":0,"is_preprint":false},{"pmid":"41367487","id":"PMC_41367487","title":"Whole Genome Sequencing Improves the Identification of Pathogenic and Novel Variation in Nonsyndromic Hearing Loss.","date":"2025","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/41367487","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15769,"output_tokens":1835,"usd":0.037416,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8767,"output_tokens":2493,"usd":0.05308,"stage2_stop_reason":"end_turn"},"total_usd":0.090496,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"Human CRYL1 encodes a protein sharing 83% identity with rabbit lambda-crystallin and contains two HCDH (3-hydroxyacyl-CoA dehydrogenase) domains, including a putative NAD- or FAD-binding domain, suggesting enzymatic activity analogous to 3-hydroxyacyl-CoA dehydrogenase. CRYL1 mRNA is highly expressed in liver and kidney but extremely low in peripheral blood leukocytes and thymus.\",\n      \"method\": \"cDNA cloning, sequence analysis, domain identification, Northern blot/expression profiling, chromosomal mapping\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 / Weak — domain identification and expression profiling from a single lab; enzymatic activity inferred from domain homology, not directly assayed\",\n      \"pmids\": [\"12527201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CRYL1 mRNA is downregulated in 58% of 60 hepatocellular carcinoma (HCC) tissue samples compared to normal liver, consistent with a tumor suppressor role.\",\n      \"method\": \"Differential gene expression analysis between liver cancer and normal tissues\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, expression-level finding without direct functional mechanism established\",\n      \"pmids\": [\"12527201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CRYL1, along with TG737 and GJB2, is significantly downregulated within a homozygous deletion region at 13q12.11 in HCC, and LOH at this locus is associated with early-onset HCC, supporting CRYL1 as a candidate tumor suppressor gene.\",\n      \"method\": \"High-density genetic marker scan, Southern blotting, LOH analysis, quantitative RT-PCR in 48 HCC tissue pairs\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative RT-PCR on patient tissue pairs with LOH analysis; multiple methods but no direct functional assay of CRYL1 protein\",\n      \"pmids\": [\"16075462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A recurrent CRYL1-IFT88 chimeric fusion transcript was identified in hepatocellular carcinoma (recurrence rate ~9.52%, 6/63 samples). The fusion transcript retains most of the CRYL1 domain structure, while the IFT88 transcript structure is entirely disrupted, potentially suppressing IFT88 tumor suppressor function.\",\n      \"method\": \"Transcriptome sequencing, RT-PCR validation, 3' and 5' RACE for full-length fusion transcript characterization\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fusion transcript validated by multiple methods (RNA-seq, RT-PCR, RACE) across multiple samples in a single study; functional consequence for IFT88 inferred bioinformatically\",\n      \"pmids\": [\"28489570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CRYL1 was identified as a cadmium-responsive gene in zebrafish embryos and adult retinae; CRYL1 (described as a lens protein with redox activity) expression was upregulated in retinal cells following cadmium exposure in a dose-dependent manner, and expression returned to baseline upon cadmium removal.\",\n      \"method\": \"In situ hybridization, dose-response analysis in zebrafish exposed to cadmium\",\n      \"journal\": \"Comptes rendus biologies\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method (ISH), functional mechanism not directly tested\",\n      \"pmids\": [\"28385620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A novel 200 kb deletion spanning the entire CRYL1 gene causes DFNB1A nonsyndromic sensorineural hearing loss when in trans with pathogenic GJB2 variants. CRYL1 deletions (overlapping a minimal common 62 kb region within CRYL1) cause loss of cis GJB2 expression, establishing that CRYL1 genomic sequences contain cis-regulatory elements required for GJB2 expression in the cochlea.\",\n      \"method\": \"Panel NGS, MLPA, whole-genome sequencing breakpoint mapping, PCR + Sanger sequencing, triple-primer PCR screening\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (NGS, WGS, MLPA, Sanger) and replicated across multiple independent deletions from different groups demonstrating the same cis-regulatory mechanism\",\n      \"pmids\": [\"40565562\", \"19101659\", \"41367487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CRYL1 overexpression in clear cell renal cell carcinoma (ccRCC) cell lines (Caki-1, OSRC-2) suppressed proliferation, colony formation, and migration, and induced apoptosis. Transcriptome sequencing identified CASR (calcium-sensing receptor) as a key downstream target upregulated by CRYL1. CASR knockdown partially reversed the anti-migratory effects of CRYL1 overexpression, establishing a CRYL1/CASR signaling axis. In vivo, CRYL1-overexpressing xenografts showed reduced tumor growth, upregulated BAX and TIMP3, and downregulated BCL2 and MMP9.\",\n      \"method\": \"In vitro proliferation, migration, and apoptosis assays; transcriptome sequencing; bioinformatics; rescue (CASR knockdown) experiments; IHC; subcutaneous xenograft mouse models\",\n      \"journal\": \"Cancer genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods from a single lab; rescue experiment places CASR downstream of CRYL1 in the pathway\",\n      \"pmids\": [\"42105605\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CRYL1 encodes a protein with two HCDH (3-hydroxyacyl-CoA dehydrogenase-like) domains and putative NAD/FAD-binding activity; it is highly expressed in liver and kidney, functions as a tumor suppressor in hepatocellular carcinoma and clear cell renal cell carcinoma (suppressing proliferation and migration at least in part by upregulating CASR), and its genomic locus contains cis-regulatory sequences essential for GJB2 cochlear expression such that deletions spanning CRYL1 cause nonsyndromic sensorineural hearing loss.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CRYL1 encodes a metabolic enzyme of the 3-hydroxyacyl-CoA dehydrogenase family, defined by two HCDH domains including a putative NAD/FAD-binding domain and 83% identity to rabbit lambda-crystallin, with mRNA expression concentrated in liver and kidney [#0]. It functions as a candidate tumor suppressor: its expression is downregulated in the majority of hepatocellular carcinomas and lost through homozygous deletion and LOH at 13q12.11, where loss correlates with early-onset disease [#1, #2]. In clear cell renal cell carcinoma, CRYL1 overexpression suppresses proliferation, colony formation, and migration and induces apoptosis, acting at least in part through upregulation of the calcium-sensing receptor CASR, whose knockdown partially reverses the anti-migratory phenotype, and in xenografts shifts the cell toward a pro-apoptotic, anti-invasive program (elevated BAX and TIMP3, reduced BCL2 and MMP9) [#6]. Independently of any protein function, the CRYL1 genomic locus harbors cis-regulatory elements required for cochlear GJB2 expression: deletions spanning CRYL1 in trans with pathogenic GJB2 variants cause DFNB1A nonsyndromic sensorineural hearing loss by abolishing cis GJB2 expression [#5]. The enzymatic activity inferred from its HCDH domains has not been directly assayed in the available corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing the molecular identity of CRYL1 was the first step: the question was what kind of protein it encodes and where it acts, answered by domain architecture and tissue expression.\",\n      \"evidence\": \"cDNA cloning, sequence/domain analysis, and Northern blot expression profiling\",\n      \"pmids\": [\n        \"12527201\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Enzymatic activity was inferred from domain homology, not directly assayed\",\n        \"No substrate identified\",\n        \"No structural model of the HCDH domains\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Whether CRYL1 expression is altered in cancer was addressed by showing downregulation in a majority of hepatocellular carcinomas, raising the tumor suppressor hypothesis.\",\n      \"evidence\": \"Differential gene expression analysis between HCC and normal liver tissue\",\n      \"pmids\": [\n        \"12527201\"\n      ],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Expression-level association only; no functional mechanism tested\",\n        \"Does not establish causality or the basis of downregulation\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The genetic basis of CRYL1 loss in liver cancer was clarified by mapping homozygous deletion and LOH at 13q12.11, supporting a candidate tumor suppressor at this locus.\",\n      \"evidence\": \"Genetic marker scan, Southern blotting, LOH analysis, and quantitative RT-PCR in HCC tissue pairs\",\n      \"pmids\": [\n        \"16075462\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct functional assay of CRYL1 protein in HCC\",\n        \"Deletion spans multiple genes (TG737, GJB2), confounding gene-specific attribution\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A recurrent CRYL1-IFT88 fusion transcript in HCC raised the possibility that CRYL1 locus rearrangement contributes to tumorigenesis by disrupting IFT88.\",\n      \"evidence\": \"Transcriptome sequencing, RT-PCR validation, and 5'/3' RACE characterization\",\n      \"pmids\": [\n        \"28489570\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence for IFT88 inferred bioinformatically, not tested experimentally\",\n        \"Role of the retained CRYL1 portion in the fusion unknown\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Whether CRYL1 responds to environmental stress was probed by showing cadmium-inducible expression in zebrafish retina, hinting at a redox-related stress role.\",\n      \"evidence\": \"In situ hybridization and dose-response analysis in cadmium-exposed zebrafish\",\n      \"pmids\": [\n        \"28385620\"\n      ],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single method (ISH); functional mechanism not tested\",\n        \"No link to the proposed enzymatic activity established\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The hearing-loss phenotype of CRYL1 deletions was resolved as a positional/cis-regulatory effect rather than loss of CRYL1 protein, showing the locus carries elements required for cochlear GJB2 expression.\",\n      \"evidence\": \"Panel NGS, MLPA, whole-genome breakpoint mapping, and Sanger sequencing across multiple independent deletions in trans with GJB2 variants\",\n      \"pmids\": [\n        \"40565562\",\n        \"19101659\",\n        \"41367487\"\n      ],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise regulatory elements and their interaction with GJB2 not mapped at base resolution\",\n        \"Does not implicate CRYL1 protein function in hearing\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"A functional tumor suppressor mechanism was finally provided by showing CRYL1 overexpression suppresses ccRCC growth and migration via upregulation of CASR.\",\n      \"evidence\": \"In vitro proliferation/migration/apoptosis assays, transcriptome sequencing, CASR-knockdown rescue, IHC, and xenograft models\",\n      \"pmids\": [\n        \"42105605\"\n      ],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab; rescue was only partial, implying additional effectors\",\n        \"Mechanism linking CRYL1 enzymatic activity to CASR transcription unknown\",\n        \"Whether the same axis operates in HCC not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct biochemical activity of CRYL1 and how it mechanistically connects to tumor suppression and downstream CASR signaling remain unresolved.\",\n      \"evidence\": \"No reconstituted enzymatic or substrate assay reported in the corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No enzymatic substrate or catalytic readout demonstrated\",\n        \"Causal chain from a metabolic/redox activity to CASR upregulation unknown\",\n        \"No structural characterization\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\n        \"term_id\": \"GO:0016491\",\n        \"supporting_discovery_ids\": [\n          0\n        ]\n      }\n    ],\n    \"localization\": [],\n    \"pathway\": [],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":4,"faith_total":4,"faith_pct":100.0}}